Xenobiotica

Papers
(The median citation count of Xenobiotica is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development22
Academic foreign compound metabolism – ‘ quo vadis ’?20
Developmental stage and infection status may affect drug distribution in the prostate of rats19
In vitro hepatic metabolism of the natural product quebecol16
Meeting report: oligonucleotide ADME workshop14
Diisononyl phthalate down-regulates the expression of antioxidant genes NFE2L2 , TXN , and TXNRD2 , while d12
Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model12
Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver11
Nrf2 signaling pathway studies in Drosophila melanogaster : parallel roles in human health and insect environmental responses10
Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J210
An In silico model-based feasibility assessment of erlotinib long-acting injectable formulation for the management of metastatic non-small cell lung cancer9
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro9
Formulation of apigenin-loaded solid lipid nanoparticles: characterisation, molecular docking, and anticancer assay9
Preparation, characterisation, pharmacokinetics and distribution of esculin microspheres administered via intravitreal injection into rabbit brain9
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor9
Apigenin derivatives as promising norovirus RdRp inhibitors: insights from in silico docking and molecular dynamics studies9
The protective effect of linalool against carbon tetrachloride-induced testicular toxicity in rats9
Methyl mercury pharmacokinetics in man: a five-compartment hybrid model8
Comparisons between human and rodent hepatic glutathione S-Transferase activities reveal sex and species differences8
Machine learning-driven bioavailability prediction in early-stage drug development: a KNIME-based computational workflow for digital health applications8
Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation8
Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers8
Arctigenin-induced erythrocyte membrane remodelling is mediated through calcium influx, metabolic collapse, and casein kinase 1α8
Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions8
The effect of ARVs on the MEKKK1 gene promoter, inflammatory cytokine expression and signalling in acute treated Jurkat T cells8
Safflower yellow for injection enhances anti-coagulation of warfarin in rats: implications in pharmacodynamics and pharmacokinetics7
Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P 1 modulator ponesimod7
Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats7
Preclinical pharmacokinetic investigation of the bioavailability and skin distribution of HY-072808 ointment, a novel drug candidate for the treatment of atopic dermatitis, in minipigs by a newly LC-M7
Exploring precision-cut liver slices for comparative xenobiotic metabolism profiling in swine and cattle7
Prediction of the neurotoxic mechanisms of the pesticide phorate using network toxicology, molecular docking, and molecular dynamics simulation7
New era in bioequivalence global harmonization through ICH M13 initiative: critical review on new concepts, alternative approaches for high-risk products7
An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds7
In vivo evaluation of pharmacokinetic drug–drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin7
Defining the enzymes of xenobiotic metabolism – a forlorn hope?7
Development of eugenol-fortified fisetin-loaded nano-invasomes gel6
2-Oxidation, 3-methyl hydroxylation, and 6-hydroxylation of skatole, a contributor to the odour of boar-tainted pork meat, mediated by porcine liver microsomal cytochromes P450 1A2, 2A19, 2E1, and 3A26
Experimental and computational models to investigate intestinal drug permeability and metabolism6
Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?6
Bioavailability and dose proportionality of a highly lipophilic phenolic antioxidant6
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir6
Beyond cytotoxic potency: disposition features required to design ADC payload6
The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma6
Nano-pharmacokinetics and pharmacodynamics of green-synthesized ZnO nanoparticles: a pathway to safer therapeutic applications6
Interactions of organophosphorus pesticides with ATP-binding cassette (ABC) drug transporters6
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human6
Mechanism of Black American Ginseng saponins in ameliorating memory dysfunction in aging mice by activating the BDNF/PI3K/AKT/CREB pathway6
Coptisine modulates the pharmacokinetics of florfenicol by targeting CYP1A2, CYP2C11 and CYP3A1 in the liver and P-gp in the jejunum of rats: a pilot study6
Effectiveness of pain care intervention combined with traditional Chinese medicine care in the perioperative care of patients with urinary stones6
Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson’s drug FLZ after multi-dose in cynomolgus monkeys6
Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities6
Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation5
Species differences in liver microsomal hydrolysis of acyl glucuronide in humans and rats5
Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection5
Characterisation of seven medications approved for attention-deficit/hyperactivity disorder usingin vitromodels of hepatic metabolism5
Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species5
Meeting report of the 3rd European Biotransformation Workshop5
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities5
Pharmacokinetics of intranasal drugs, still a missed opportunity?5
Preface for special issue: “Emerging strategies, technologies, and approaches for the next generation ADCs”5
Impact of tectoridin on the pharmacokinetics of florfenicol via targeting cytochrome P450 and P-glycoprotein of rats5
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective5
Sanguinarine-induced proteomic changes in methicillin-resistant Staphylococcus aureus5
The chlorophenoxy herbicide MCPA: a mechanistic basis for the observed differences in toxicological profile in humans and rats versus dogs5
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)4
Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration4
Physiologically based pharmacokinetic (PBPK) modelling and simulation based integrative approach to assess natural product-drug interactions – effect of glycyrrhetinic acid on quetiapine4
Drug-drug interaction between danshensu and irbesartan and its potential mechanism4
The impact of CYP3A5 , NR1I2 , and POR polymorphisms on tacrolimus dose-adjusted concentration and clinical4
Potential influence of interleukin-6 -174G/C gene polymorphism on kidney graft function and tacrolimus dose requirements: five-year follow-up4
Studies addressing potential bioactivation and genotoxicity liabilities of the N -nitroso derivative of the antidepressant paroxetine4
Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury4
How predictive are isolated perfused liver data of in vivo hepatic clearance? A meta-analysis of isolated perfused rat liver data4
Use of a machine learning approach to estimate pathobiological effects of crack cocaine administration in rats4
In vitro evaluation of norwogonin as a potential inhibitor of cytochrome P450 forms 3A4, 2D6, and 2C94
EP300/HIF-1 pathway: the key to sacubitril valsartan sodium alleviating myocardial hypoxia injury4
Perspectives on the use of machine learning for ADME prediction at AstraZeneca4
The mitochondrial protective mechanisms mediated by SGLT2i: from molecular basis to clinical implications4
Sodium dodecylbenzene sulphonate (SDBS) present in detergents: action on the gills, skin, and blood of D. rerio fish4
A physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the insecticide dimethoate4
Inorganic mercury pharmacokinetics in man: a hybrid model4
Meeting report: DMDG peptide and oligonucleotide ADME workshop 20244
Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats4
Study of the urinary metabolites of 17ɑ-methyl-19-nortestosterone in human using gas chromatography – mass spectrometry. Preliminary results4
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects4
Preclinical pharmacokinetics, metabolism, and disposition of NXE0041178, a novel orally bioavailable agonist of the GPR52 receptor with potential for treatment of schizophrenia and related psychiatric3
Biochemical responses of the mussel Perna perna after exposure to environmental concentrations of the UV filter Benzophenone-33
Analysis of the therapeutic potential of astragalin: insights into target interactions and mechanisms3
A discovery biotransformation strategy: combining in silico tools with high-resolution mass spectrometry and software-assisted data analysis for high-throughput metabolism3
Potential application of mass spectrometry imaging in pharmacokinetic studies3
Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs3
Determination of enzymatic kinetics of metabolism of dimethoate and omethoate in rats and humans3
Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats3
Bidirectional relationship between statins and the gut microbiota: implications for cardiovascular health, diabetes, and cancer3
Study on the transport and internalisation mechanism of dietary supplement nattokinase in the small intestine using animal and Caco-2 cell monolayer models3
Meeting report: DMDG peptide and oligonucleotide ADME workshop 20223
The metabolism of the dual orexin receptor antagonist daridorexant3
Feature-based molecular networking updates the in vitro metabolic characterisation of fenbendazole across species3
N, N -dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation3
Unravelling the toxic potential of imidacloprid and chlorothalonil in thyroid, liver, and kidney of rats: a combined experimental and computational investigations3
Behavioural toxicodynamics and kinetic profiling of PCB congeners in Swiss Albino mouse dosed with Aroclor 1232 through inhalational route: a pivotal risk assessment study3
Calycosin improves insulin resistance by regulating the hsa-miR-324-3p/AKT pathway to inhibit FOXO3a nuclear transfer3
Green synthesis of Zinc Oxide nanoflowers using camellia sinensis extract and evaluation of their xenobiotic-like cellular, apoptotic, and inflammatory r3
Qualitative and quantitative status of cytochrome P450s after the administration of a liposomal platelet substitute in rat liver3
Prediction of pharmacokinetics of an anaplastic lymphoma kinase inhibitor in rat and monkey: application of physiologically based pharmacokinetic model as an alternative tool to minimise animal studie3
Liver microsomal cytochrome P450 3A-dependent drug oxidation activities in individual dogs3
Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-15593
Benzophenone-3 (oxybenzone) in zebrafish: histopathological and oxidative stress analysis3
Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models3
Mirogabalin, a novel α2δ ligand, is not a substrate of LAT1, but of PEPT1, PEPT2, OAT1, OAT3, OCT2, MATE1 and MATE2-K3
Effect of tubeimoside I on the activity of cytochrome P450 enzymes in human liver microsomes3
Thank you to reviewers3
Investigation of pharmacokinetic properties of a PEGylated bilirubin nanoparticle in male Sprague-Dawley rats using liquid chromatography-quadrupole time-of-flight mass spectrometry3
Permethrin disrupts antioxidant defense responses in Litopenaeus vannamei3
Justification of widened dissolution specifications of an extended-release product using physiologically based biopharmaceutics modeling2
Comprehensive characterization and optimization of Caco-2 cells enabled the development of a miniaturized 96-well permeability assay2
Mass balance and metabolite profiling of 14 C-Zalunfiban in humans following single-dose subcutaneous administration2
Exploring ethanol’s toxicity in the oral submucosa: chronic exposure versus abstinence in C57BL/6 mice2
Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies2
Fluoxetine as an antidepressant agent induces directly deleterious effects on rat isolated pancreatic mitochondria: ameliorative role of betanin2
Effects of different doses of dexmedetomidine combined with stellate ganglion block in patients undergoing laparoscopic radical resection of colorectal cancer2
A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist2
Meeting report: DMPK optimisation strategies and quantitative translational PKPD frameworks to predict human PK and efficacious dose of targeted protein degraders2
Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer2
The orexin 1-selective receptor antagonist nivasorexant is a time-dependent inhibitor of CYP2C19 and CYP3A42
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development2
Tree shrew cytochrome P450 2E1 is a functional enzyme that metabolises chlorzoxazone and p -nitrophenol2
Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance2
Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and2
Prediction of the liver safety profile of a first-in-class myeloperoxidase inhibitor using quantitative systems toxicology modeling2
Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy2
Evaluation of the non-linearity of NA808 in liver not reflected in plasma using a rat pharmacokinetic study and PBPK modelling2
Use of stable isotope labeled (SIL) antibodies in cassette dosing to improve pharmacokinetics screening efficiency of ADCs with novel cytotoxic payloads2
Effects of ABCG2 421C > A genetic polymorphism on the pharmacokinetics of rivaroxaban in healthy Chinese subjects2
Investigation on the in vitro metabolism of bicyclol using liver microsomes, hepatocytes and human recombinant cytochrome P450 enzymes2
Metabolite characterisation of the peptide–drug conjugate LN005 in liver S9s by UHPLC-Orbitrap-HRMS2
Pharmacokinetic interaction between pachymic acid and tacrolimus and its potential mechanisms in rats2
Synthesis and evaluation of indomethacin prodrugs with a diester structure that are metabolically activated by human carboxylesterases2
Exposure to crack cocaine induces genotoxicity and degenerative changes in multiple organs of Wistar rats2
Metabolism and disposition of zamicastat in rats2
In vitro anti-glucocorticoid osteoporosis effect of Serfurosterone A and its intestinal absorption characteristics2
MRM-driven metabolomic workflow for early detection of antibiotic-triggered sub-lethal toxicity using Q-TRAP and zebrafish model2
Chronic Toxoplasma infection affects gene expression of drug-metabolizing enzymes in mouse liver2
In vitro and in vivo metabolic profiling of PD105, a PI3Kδ inhibitor, using UHPLC-Q-Exactive plus-MS2
Mechanism-based inactivation of cytochrome P450 3A by evodol2
Identification, structural elucidation and nonclinical characterisation of oxMET1: a further major metabolite of xevinapant?2
The pharmacokinetics of dabigatran in a rat model of hyperlipidaemia induced by poloxamer 4072
Metabolic exhaustion and casein kinase 1α drive deguelin-induced premature red blood cell death2
Exploring the pharmacokinetics of second-generation cephalosporin, cefaclor: a systematic review in healthy and diseased populations1
In vitro safety evaluation of (6-methoxy-9-oxo-9 H -xanthen-2-yl)methyl ( E )-3-(2,4-dimethoxyphenyl)acrylate (K-116) –1
Determination of free fraction (fu) of compounds by flux dialysis using the rapid equilibrium dialysis (RED) device: establishing empirical permeability for rapid estimation1
Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations1
Changes in the expression of drug-metabolising enzymes and drug transporters in mice with collagen antibody-induced arthritis1
Do differences in cell lines and methods used for calculation of IC50 values influence categorisation of drugs as P-glycoprotein substrates and inhibitors?1
The impact of ibuprofen on valproic acid plasma concentration in pediatric patients1
In vitro and in vivo studies on the metabolism and pharmacokinetics of the selective gut microbial β-glucuronidase targeting compound Inh 11
Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients1
Meeting report of the 5th European Biotransformation Workshop1
Comparative metabolism of THCA and THCV using UHPLC-Q-Exactive Orbitrap-MS1
Rehmannioside A inhibits the activity of CYP3A4, 2C9 and 2D6 in vitro1
The metabolic activation of and platelet response to vicagrel vary with P-glycoprotein deficiency, rather than P-glycoprotein inhibition, in mice1
Regulatory effect of atorvastatin combined with berberine on PI3K/AKT/FoxO1 signaling pathway in rats with hyperlipidaemia1
Impact of Terminalia ivorensis on drug metabolising and antioxidant enzyme activities, hepatotoxicity and genotoxicity in human liver cells 1
In silico analysis of nicotine’s molecular targets in Parkinson’s disease1
Quantitative prediction of drug-drug interactions arising from CYP3A4 induction using chimeric mice with humanized liver1
α-Hederin inhibits osteosarcoma progression by triggering ferroptosis and disrupting mitochondrial function via PI3K/AKT signalling1
Metabolite profiling and identification of enzymes responsible for the metabolism of hirsutine, a major alkaloid from Uncaria rhynchophylla1
Through a computer monitor darkly: artificial intelligence in absorption, distribution, metabolism and excretion science1
Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans1
Clinical pharmacokinetics of cefixime: a systematic review1
Pharmacokinetics and tissue distribution of intranasal administration of rapamycin in rats1
Crack cocaine exposure leads to developmental alterations and mitochondrial dysfunction in the Drosophila melanogaster model1
Prediction of combination effect of quinidine on the pharmacokinetics of tipepidine using a physiologically based pharmacokinetic model1
Two curcumin analogs inhibited the function and protein expression of breast cancer resistance protein: in vitro and in vivo studies1
A general perspective for the conduct of radiolabelled distribution, metabolism, and excretion studies for antibody-drug conjugates1
Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900) following a single oral dose in healthy male participants1
4,4’-Methylene diphenyl diisocyanate exposure induces expression of alternatively activated macrophage-associated markers and chemokines partially through Krüppel-like factor 4 mediated signaling in m1
Comparing the pharmacokinetics and organ/tissue distribution of anti-methicillin-resistant Staphylococcus aureus agents using a rat model of sepsis1
In vitro-in vivo extrapolation of intrinsic clearance based on data from human hepatocyte spheroids – a case study with the low-clearance drug xevinapant1
Danazol increases the oral bioavailability of midazolam by inactivation of hepatic and intestinal CYP3A in rats1
Cytotoxic effects of flurbiprofen on rat adipose-derived stem cells1
A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers1
Indirubin mediates adverse intestinal reactions in guinea pigs by downregulating the expression of AchE through AhR1
The 50th anniversary of the DMDG1
Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human1
Protective effect of carvacrol in a cardiac myoblast cell model of myocardial ischaemia-reperfusion injury1
Inhibition of YAP can down-regulate NLRP3 inflammasome and improve anti-tuberculosis drug-induced liver injury1
CYP-catalysed cycling of clozapine and clozapine- N -oxide promotes the generation of reactive oxygen species in vitro1
Fluorescent dyes as functional probes for studying drug-transporting solute carriers1
Toxicokinetic and mass balance of morpholine in rats1
Characterisation of intravenous pharmacokinetics in Göttingen minipig and clearance prediction using established in vitro to in vivo extrapolation methodologies1
Model-based steady state pharmacokinetic predictions using high throughput cassette infusion approach in mice1
Optimising pirfenidone dosage regimens in idiopathic pulmonary fibrosis: towards a guide for personalised treatment1
Development and validation of a highly sensitive and selective LC-MS/MS method for the determination of 15-hydroxylubiprostone in human plasma: application to a pharmacokinetic study in healthy Chines1
Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets1
Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity1
Correction1
Assessment of cytochrome P450 induction in canine intestinal organoid models1
ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties1
Hydrogen sulfide replenishment ameliorates impaired platelet response to clopidogrel in mice with experimental diabetes mellitus1
Pharmacokinetics of the novel 5-HT 4 receptor agonist, DA-6886, in dogs1
MicroRNA-mediated Krüppel-like factor 4 upregulation induces alternatively activated macrophage-associated marker and chemokine transcription in 4,4’-methylene diphenyl diisocyanate exposed macrophage1
Combination of losartan and puerarin induced pharmacokinetic interaction in hypertension rats enhances the antihypertensive effect of losartan1
Preclinical metabolism and disposition of [ 14 C]GFH009, a novel selective CDK9 inhibitor1
The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants in vitro1
Use of selective substrates and inhibitors to rapidly characterise batches of cryopreserved primary human hepatocytes for assessment of active uptake liability in drug discovery and development1
The metabolism of the orexin-1 selective receptor antagonist nivasorexant1
Population pharmacokinetics of mycophenolic acid and dose optimisation in adult Chinese kidney transplant recipients1
Teratogenicity is more likely a function of primary and secondary pharmacology than caused by chemically reactive metabolites: a critical evaluation of 40 years of scientific research1
0.1984760761261